Deep Vein Thrombosis (DVT) and DVT Prophylaxis

Adil Abbasi, MD FACP FACN

Learning Objectives

• Define deep vein thrombosis (DVT) and explain its clinical importance.
• Describe the incidence and prevalence of DVT in common medical and surgical conditions.
• Differentiate lower-extremity, upper-extremity, and pelvic venous thrombosis.
• Recognize major acquired and inherited causes of venous thrombosis.
• Review modern management strategies for acute DVT and prevention of recurrence.
• Identify complications of DVT, including pulmonary embolism and post-thrombotic syndrome.
• Explain superficial venous thrombosis and its relationship to DVT.
• Apply evidence-based DVT prophylaxis strategies for hospitalized medical and surgical patients.

Introduction

Deep vein thrombosis refers to thrombus formation within the deep venous circulation, most commonly in the lower extremities, but also in the upper extremities and pelvic veins. DVT and pulmonary embolism together comprise venous thromboembolism (VTE), a major source of preventable morbidity and mortality worldwide. Thrombi may remain localized, propagate proximally, embolize to the pulmonary arteries, or lead to chronic venous damage.

Hospital-associated VTE remains one of the most common preventable causes of inpatient death. The risk rises substantially in the presence of surgery, trauma, immobility, malignancy, infection, heart failure, inflammatory illness, stroke, pregnancy, and inherited thrombophilia. Appropriate prophylaxis significantly lowers the rates of symptomatic DVT, pulmonary embolism, and fatal PE.

The pathogenesis of DVT is classically explained by Virchow’s triad: venous stasis, endothelial injury, and hypercoagulability. Most clinical episodes involve more than one component of this triad.

Epidemiology and Incidence in Various Clinical Conditions

The annual incidence of first-time VTE in adults is approximately 1 to 2 per 1,000 persons, increasing sharply with age. Incidence is lower in younger adults and markedly higher in patients older than 70 years. Many hospital-acquired episodes occur in the weeks following discharge, particularly after surgery.

Without prophylaxis, certain patient populations demonstrate particularly high risk for developing DVT.

Table 1. Approximate Relative Risk of DVT/VTE in Common Clinical Settings Without Prophylaxis

Modern prophylaxis has reduced these historical rates substantially, but risk persists if preventive strategies are omitted.

Types and Causes of DVT

Lower Extremity DVT

Lower-extremity DVT is the most common form and may be divided into distal and proximal thrombosis.

Distal DVT involves the calf veins, including posterior tibial, anterior tibial, peroneal, gastrocnemius, and soleal veins. Distal thrombi may remain localized or propagate proximally.

Proximal DVT involves the popliteal, femoral, common femoral, or iliac veins. Proximal clot carries greater risk of pulmonary embolism and long-term venous insufficiency.

Common causes include immobility, recent surgery, trauma, obesity, malignancy, estrogen exposure, pregnancy, prior VTE, inflammatory disease, and inherited thrombophilia.

Upper Extremity DVT

Upper-extremity DVT involves the brachial, axillary, subclavian, internal jugular, or more proximal veins. Incidence has risen due to widespread use of central venous catheters and peripherally inserted central catheters (PICCs).

Primary upper-extremity DVT may occur with thoracic outlet compression or strenuous repetitive arm activity (Paget-Schroetter syndrome). Secondary causes include catheters, pacemaker leads, malignancy, and hospitalization.

Pelvic / Iliac Vein Thrombosis

Pelvic thrombosis may involve the iliac veins, ovarian veins, uterine plexus, or other pelvic venous structures. It may be underdiagnosed because standard leg ultrasound may not visualize the pelvis adequately.

Common causes include malignancy, pregnancy/postpartum state, pelvic surgery, large uterine masses, inflammatory pelvic disease, and venous compression syndromes such as May-Thurner syndrome.

Clinical Presentation

Symptoms depend on clot location, extent, and associated inflammation.

Lower-extremity DVT often presents with unilateral leg swelling, calf or thigh pain, warmth, erythema, tenderness, and superficial collateral veins. Massive iliofemoral thrombosis may cause marked swelling, cyanosis, and severe pain.

Upper-extremity DVT may present with arm swelling, heaviness, cyanosis, neck fullness, collateral chest wall veins, and discomfort exacerbated by arm movement.

Pelvic DVT may present with diffuse leg swelling, groin pain, buttock pain, unexplained fever, or pulmonary embolism without obvious leg findings.

Many patients are asymptomatic until PE occurs.

Diagnostic Evaluation

Clinical prediction rules such as the Wells score help stratify pretest probability. In low-risk patients, a negative D-dimer may help exclude DVT. In moderate- or high-risk patients, imaging is generally required.

Compression ultrasonography is first-line for suspected lower-extremity DVT. Duplex ultrasound adds Doppler flow information. CT venography or MR venography may be useful for pelvic or iliac thrombosis. Upper-extremity duplex ultrasound is commonly used for catheter-associated thrombosis.

Table 2. Common Diagnostic Modalities

Management of Acute DVT

Anticoagulation is the cornerstone of treatment unless contraindicated. Goals include preventing clot extension, pulmonary embolism, recurrence, and chronic venous complications.

Direct oral anticoagulants such as Apixaban and Rivaroxaban are widely used in many patients. Enoxaparin remains common, particularly in malignancy, pregnancy, or transitional settings. Warfarin remains useful in selected patients.

Provoked DVT due to surgery or temporary risk factors is commonly treated for approximately three months. Unprovoked proximal DVT may warrant extended therapy depending on bleeding risk. Cancer-associated thrombosis often requires prolonged anticoagulation while malignancy remains active.

Catheter-directed thrombolysis or thrombectomy may be considered in selected patients with extensive iliofemoral thrombosis, threatened limb, or severe symptoms. Inferior vena cava filters are generally reserved for patients with acute proximal DVT and a contraindication to anticoagulation.

Complications

Pulmonary embolism is the most feared acute complication and may be fatal. Recurrent thrombosis can occur during or after therapy. Post-thrombotic syndrome results from chronic venous valve damage and manifests such as edema, pain, heaviness, hyperpigmentation, and venous ulceration.

Rare but severe complications include phlegmasia alba dolens and phlegmasia cerulea dolens, which may threaten limb viability.

Table 3. Major Complications of DVT

Superficial Venous Thrombosis

Superficial venous thrombosis (SVT), historically termed superficial thrombophlebitis, involves clot within superficial veins such as the great saphenous or small saphenous systems. Patients often present with localized pain, erythema, tenderness, and a palpable cord.

Although less dangerous than DVT, SVT is clinically important because extension into the deep venous system may occur, particularly when the thrombus is near the saphenofemoral or sapheno-popliteal junction.

Localized limited SVT may be managed with ambulation, compression, anti-inflammatory measures, and symptom control. More extensive SVT, thrombosis >5 cm, recurrent disease, or clot near deep venous junctions may warrant anticoagulation.

DVT Prophylaxis

General Principles

All hospitalized patients should undergo VTE risk assessment along with bleeding-risk assessment. Preventive strategies include early mobilization, mechanical prophylaxis, pharmacologic prophylaxis, or combinations thereof.

Mechanical methods are favored when bleeding risk is high. Pharmacologic methods are generally more effective when bleeding risk is acceptable.

Mechanical Prophylaxis

Mechanical prophylaxis improves venous flow and reduces stasis. Intermittent pneumatic compression devices are more effective than stockings alone when used consistently.

Table 4. Mechanical Methods

Pharmacologic Prophylaxis

Common agents include unfractionated heparin, low molecular weight heparin, fondaparinux, and selected direct oral anticoagulants in postoperative orthopedic settings.

Table 5. Pharmacologic Options

Prophylaxis by Clinical Condition

Table 6. Practical DVT Prophylaxis by Diagnosis

Contraindications to Pharmacologic Prophylaxis

Active bleeding, severe thrombocytopenia, uncontrolled coagulopathy, recent hemorrhagic stroke, and certain neuraxial procedural time windows may require temporary avoidance of anticoagulants.

______________________________________________________________________________

Aspirin as DVT Prophylaxis

Aspirin can be used as DVT/VTE prophylaxis in selected situations, but it is not the strongest or most universally preferred option. It is most commonly considered in orthopedic postoperative settings (especially after hip or knee replacement) or when full anticoagulants are undesirable, contraindicated, or being stepped down from. It is not usually first-line for high-risk hospitalized medical patients, active cancer, trauma, or acute immobility.

How Aspirin Works

Aspirin inhibits platelet aggregation by irreversibly blocking cyclooxygenase-1 (COX-1) and reducing thromboxane A2. That mechanism is excellent for arterial thrombosis (heart attack, stroke), but venous thrombosis is more fibrin/coagulation-factor driven. Therefore:

• Excellent for arterial clot prevention 
• Modestly effective for venous clot prevention 
• Usually weaker than anticoagulants like Enoxaparin, Apixaban, or Rivaroxaban

Where Aspirin Is Commonly Used

1. After Joint Replacement Surgery

After Total Knee Arthroplasty or Total Hip Arthroplasty, many surgeons use aspirin in low-to-moderate risk patients, especially after an initial short course of stronger anticoagulation.

Typical strategies:

• Short course of LMWH/DOAC, then aspirin
• Aspirin alone in carefully selected low-risk patients
• Aspirin + early ambulation + compression devices

This has become common because aspirin is inexpensive, oral, and lower bleeding risk than stronger anticoagulants.

2. Extended Prevention After Prior Unprovoked VTE

Sometimes used after completing standard anticoagulation when long-term full-dose anticoagulation is not chosen. It offers some recurrence reduction, but less than continued anticoagulation.

Where Aspirin Is Usually Not Enough Alone

Aspirin alone is generally weaker and often not preferred for:

• Active cancer
• ICU patients
• Major trauma
• Spinal cord injury
• Large pelvic/abdominal cancer surgery
• Acute stroke with paresis
• Known thrombophilia with high risk
• Prior recurrent DVT/PE
• Prolonged immobilization with multiple risk factors

These patients often need LMWH or DOAC-class prophylaxis if bleeding risk allows.

Relative Effectiveness (General)

Typical Aspirin Doses Used in Orthopedics

Common regimens include:

• 81 mg twice daily
• 325 mg twice daily

Protocols vary by surgeon and institution.

Important Risks of Aspirin

Even though it feels “mild,” aspirin can still cause:

• GI bleeding
• Gastritis / ulcer
• Bruising
• Hemorrhagic stroke (rare)
• Kidney issues in some people
• Asthma sensitivity in susceptible patients

Practical Bottom Line

Aspirin is reasonable when:

• Lower-risk patient after hip/knee replacement
• Step-down after short stronger anticoagulation
• Need lower-cost oral option
• Bleeding risk makes stronger agents less attractive

Aspirin is usually insufficient when:

• Patient is high VTE risk
• Prior serious clot history
• Cancer/trauma/ICU
• Severe immobility

Summary

• DVT is a common and potentially fatal manifestation of venous thromboembolism.
• Lower-extremity proximal DVT carries the greatest risk of pulmonary embolism.
• Upper-extremity DVT is increasingly associated with catheters and devices.
• Pelvic DVT may be missed if imaging is limited to the legs.
• Anticoagulation is the primary treatment for most acute DVT.
• Major complications include PE, recurrence, and post-thrombotic syndrome.
• Superficial venous thrombosis may extend into the deep system and should not be dismissed.
• Hospitalized medical and surgical patients should receive formal VTE risk assessment.
• LMWH is among the most commonly used prophylactic agents.
• Orthopedic and cancer surgery patients often benefit from extended prophylaxis.

References

Kearon, C., et al. 2016. Antithrombotic Therapy for VTE Disease. Chest.

Anderson, D.R., et al. 2019. Prevention of VTE in Surgical Hospitalized Patients. Blood Advances.

Schünemann, H.J., et al. 2018. American Society of Hematology Guidelines for Management of VTE. Blood Advances.

Spyropoulos, A.C., et al. 2020. Prevention of Venous Thromboembolism in Hospitalized Medical Patients. Journal of Thrombosis and Haemostasis.

Di Nisio, M., van Es, N., Buller, H.R. 2016. Deep Vein Thrombosis and Pulmonary Embolism. Lancet.

Decousus, H., et al. 2010. Fondaparinux for Superficial-Vein Thrombosis. New England Journal of Medicine.

Geerts, W.H., et al. 2008. Prevention of Venous Thromboembolism. Chest.